In a recent clinical study, patients with NSCLC refractory to PD-1 blockade showed signs of clinical responses to the PD-1 targeting antibody nivolumab when given in combination with the IL-15 superagonist N-IL15 (previous known as ALT803). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.